TNFRSF8 and neoplasm: CD30 immunostains were scored using a semiquantitative evaluation of the percentage of CD30+ tumor cells on a five-tiered scale (IHC scores: score 0, <5% of CD30+ tumor cells; score 1, 5 to 24%; score 2, 25 to 49%; score 3, 50 to 75%; score 4, >75%).